X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs AUROBINDO PHARMA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA AUROBINDO PHARMA ASTRAZENECA PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 114.6 15.6 732.4% View Chart
P/BV x 16.3 4.0 406.3% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 ASTRAZENECA PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
AUROBINDO PHARMA
Mar-17
ASTRAZENECA PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,285895 143.6%   
Low Rs634622 101.9%   
Sales per share (Unadj.) Rs189.6254.6 74.5%  
Earnings per share (Unadj.) Rs-0.239.3 -0.5%  
Cash flow per share (Unadj.) Rs3.846.6 8.3%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs68.6160.0 42.9%  
Shares outstanding (eoy) m25.00585.88 4.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x5.13.0 169.9%   
Avg P/E ratio x-4,712.719.3 -24,403.7%  
P/CF ratio (eoy) x249.616.3 1,532.6%  
Price / Book Value ratio x14.04.7 294.8%  
Dividend payout %06.4 0.0%   
Avg Mkt Cap Rs m23,988444,390 5.4%   
No. of employees `0001.614.0 11.2%   
Total wages/salary Rs m1,60517,678 9.1%   
Avg. sales/employee Rs Th3,040.210,667.8 28.5%   
Avg. wages/employee Rs Th1,029.21,264.3 81.4%   
Avg. net profit/employee Rs Th-3.31,645.8 -0.2%   
INCOME DATA
Net Sales Rs m4,740149,157 3.2%  
Other income Rs m921,159 7.9%   
Total revenues Rs m4,832150,316 3.2%   
Gross profit Rs m-13034,343 -0.4%  
Depreciation Rs m1014,276 2.4%   
Interest Rs m0667 0.0%   
Profit before tax Rs m-13930,558 -0.5%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m57,597 0.1%   
Profit after tax Rs m-523,012 -0.0%  
Gross profit margin %-2.723.0 -11.9%  
Effective tax rate %-3.724.9 -14.7%   
Net profit margin %-0.115.4 -0.7%  
BALANCE SHEET DATA
Current assets Rs m2,72692,062 3.0%   
Current liabilities Rs m2,43566,223 3.7%   
Net working cap to sales %6.117.3 35.5%  
Current ratio x1.11.4 80.5%  
Inventory Days Days74106 69.6%  
Debtors Days Days4168 60.2%  
Net fixed assets Rs m1,03562,919 1.6%   
Share capital Rs m50586 8.5%   
"Free" reserves Rs m94293,133 1.0%   
Net worth Rs m1,71693,719 1.8%   
Long term debt Rs m01,814 0.0%   
Total assets Rs m4,156162,494 2.6%  
Interest coverage xNM46.8-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.10.9 124.2%   
Return on assets %-0.114.6 -0.8%  
Return on equity %-0.324.6 -1.2%  
Return on capital %032.7 0.0%  
Exports to sales %5.70-   
Imports to sales %6.50-   
Exports (fob) Rs m270NA-   
Imports (cif) Rs m306NA-   
Fx inflow Rs m37575,838 0.5%   
Fx outflow Rs m47030,224 1.6%   
Net fx Rs m-9645,613 -0.2%   
CASH FLOW
From Operations Rs m-832,786 -0.0%  
From Investments Rs m-146-17,870 0.8%  
From Financial Activity Rs m862-19,153 -4.5%  
Net Cashflow Rs m709-4,239 -16.7%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 8.0 3.8%  
FIIs % 15.7 27.7 56.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.2 89.2%  
Shareholders   12,856 69,601 18.5%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   GLENMARK PHARMA  FULFORD INDIA  DR. REDDYS LAB  DIVIS LABORATORIES  UNICHEM LAB  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jan 19, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS